CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today will present an overview of its proprietary pipeline at its Research and Development (R&D) Day meeting for analysts and investors in Cambridge, Massachusetts. For the first time, the company will detail its advancing portfolio of novel small molecules targeting opioid receptor pathways, which are implicated in a broad range of nervous system disorders. During the meeting, the company will also describe the scientific rationale and commercial opportunities for these product candidates and present positive topline data from a phase 1 study of ALKS 33, an opioid modulator with potential benefits in addiction and other nervous system disorders.
